Postmenopausal breast cancer patients (stages 0–III) who had completed anticancer treatment and received an oral supplement of melatonin (3 mg/day for 4 months) did not significantly improve the levels of serum biomarkers (estradiol, IGF1, IGFBP-3) related to breast cancer [88]. The gene discussed is IGF1; the disease is breast cancer.